– Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx)™ technology for the treatment of rare genetic and neurodegenerative diseases – The collaborative agreement …
Search Results “Project”
Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024 BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, …
GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology …
BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …
BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …
GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models …
BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …
GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, …
This September Gain Therapeutics is attending and presenting at two conferences. H.C. Wainwright 26th Annual Global Investment Conference The H.C. Wainwright 26th Annual Global Investment …
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule BETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, …
HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International …
BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development …
We’re back with Ana Maria Garcia-Collazo, Ph.D. of Gain Therapeutics. We ended Part 1 of our interview talking about the intersection of chemistry and computational …
Wisdom is not hard to come by. Passion and enthusiasm are a different story. On a bright and sunny Thursday morning in April 2023, Ana …
BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development …
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical …
BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule …
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease BETHESDA, Md., March 29, 2023 (GLOBE …
Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease …
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency BETHESDA, Md., …
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, …
Gain to present new preclinical data on its lead programs in GBA1-related diseases BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: …
You joined Gain Therapeutics in 2020 when it was a private company and played a role in helping to take the company public. What was …
Listen to Podcast Watch the full presentation video of Computational Drug Discovery With Gain Therapeutics Matthias Alder In conversation with Mathias Alder, CEO of Gain …
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief …
Watch the full presentation video of Jeff Harman with Eric Richman, CEO of Gain Therapeutics: 00:01 I am Jeff Harmon 00:14 Eric Richman 00:19 Gain …
Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story. You can follow him on : Twitter : @ManoloBellotto LinkedIn : https://www.linkedin.com/in/manolobellotto/ …
Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about discovering Novel Allosteric Targets by Combining Advances in Big Data and Computational Technology. …